The GLP is committed to full transparency. Download and review our just-released 2019 Annual Report.

Gene therapy applied to peripheral arterial disease

| | August 22, 2012

Hepatocyte growth factor (HGF) gene therapy could be used to treat patients with severe peripheral arterial disease (PAD), suggest results of a phase I clinical trial.

This finding could be “cautiously interpreted” to indicate that intramuscular injection of naked plasmid DNA encoding HGF is safe, feasible, and can achieve successful improvement of ischemic limbs as sole therapy, remark Ryuichi Morishita (Osaka University, Japan) and team.

In a previous study by the researchers, ankle-brachial pressure index (ABI) was significantly increased in patients with PAD who were treated with HGF from 0.46 at baseline to 0.59 at 8 weeks after injection.

View the original article here: Gene therapy applied to peripheral arterial disease – News-Medical.net

The GLP aggregated and excerpted this article to reflect the diversity of news, opinion, and analysis. Click the link above to read the full, original article.
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend